2025-11-23 - Analysis Report
Okay, here's a comprehensive report analyzing Intuitive Surgical (ISRG) based on the provided data.

## Intuitive Surgical Inc (ISRG) Report

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** ISRG
*   **Company Overview:** Intuitive Surgical is a pioneer in robotic-assisted surgery, designing, manufacturing, and marketing the da Vinci surgical system.
*   **ISRG Cumulative Return:** 108.40%
*   **VOO Cumulative Return:** 94.64%
*   **Absolute Deviation (ISRG - VOO):** 13.76%
*   **Deviation Range:** Max: 99.0, Min: -37.7, Current: 5.5
*   **Relative Deviation:** 31.6

**Analysis:** ISRG has outperformed the S&P 500 over the analyzed period, with a cumulative return exceeding VOO by 13.76%. The relative deviation of 31.6 indicates that ISRG's outperformance is positioned in the lower half of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 77.6% | 41.0% | -0.1 | 43.6 |
| 2016-2018  | 64.0% | 72.2% | 48.0% | -0.0 | 57.2 |
| 2017-2019  | 54.0% | 72.2% | 31.0% | 0.2 | 70.6 |
| 2018-2020  | -6.0% | 80.4% | -29.0% | 0.2 | 97.8 |
| 2019-2021  | 29.0% | 80.4% | -18.0% | 0.5 | 128.8 |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2 | 95.1 |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7 | 120.9 |
| 2022-2024  | 36.0% | 77.5% | 15.0% | 1.7 | 187.1 |
| 2023-2025  | 71.0% | 72.7% | 11.0% | 0.8 | 201.3 |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate varies significantly across periods, showing high growth in some and decline in others. The most recent period shows a strong 71%.
*   **MDD:** Maximum Drawdown indicates significant potential downside risk.
*   **Alpha:**  Alpha fluctuates, indicating periods of both outperformance and underperformance relative to its benchmark. More recent periods tend to have lower to negative alphas.
*   **Beta:** Beta has generally increased over time, suggesting ISRG's price has become more sensitive to market movements (more volatile).  Recent betas are relatively high (above 1), meaning it moves more than the market.
*   **Market Cap:** Market capitalization has generally increased over the periods, reflecting the company's growth.

**2. Recent Price Action**

*   **Current Close:** $561.61
*   **Previous Close:** $552.23
*   **Change:** 1.7% (Significant Positive Change)
*   **5-Day Moving Average:** 554.39
*   **20-Day Moving Average:** 552.25
*   **60-Day Moving Average:** 486.31

**Analysis:** The recent 1.7% price increase suggests positive momentum. The current price is above all three moving averages, indicating an upward trend, especially the 60-day moving average, which is significantly lower. This recent surge warrants attention as it could signal a breakout.

**3. Technical Indicators & Expected Return**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 58.35 (Neutral - Neither Overbought nor Oversold)
*   **PPO:** -0.73 (Slightly Bearish - Below Zero)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20-day) Relative Deviation Change:** -3.0 (Short-Term Decline)
*   **Expected Return:** 27.2% (Long-Term, vs. S&P 500)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI is neutral. The PPO is slightly bearish. The hybrid signal recommends buying. The negative change in relative deviation suggests some recent weakness compared to the benchmark. The expected return is a significant positive for long-term investors.

**4. Recent News & Significant Events**

*   **Positive Coverage:** Several articles highlight positive aspects of ISRG, including its recent outperformance, breakout above the 20-day moving average, and long-term investment potential.
*   **Analyst Recognition:** Featured in Zacks Analyst Blog, indicating continued attention from analysts.
* Bruker Stock Earns Relative Strength Rating Upgrade

**Analysis:** Recent news is overwhelmingly positive, focusing on the company's financial performance, stock movements, and analyst recognition. This positive media coverage likely contributes to investor confidence.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean Rating: 2.00)
*   **Target Price:** Average: $592.96, High: $700.00, Low: $378.00

**Analysis:** Analyst consensus is a "Buy" with a significant average target price above the current price, suggesting potential upside. The wide range in target prices ($378 to $700) indicates varied opinions on the stock's potential.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-10-22 | 1.98 | 2.51 B$ |
| 2025-07-23 | 1.84 | 2.44 B$ |
| 2025-04-23 | 1.95 | 2.25 B$ |
| 2024-10-18 | 1.59 | 2.04 B$ |
| 2025-10-22 | 1.59 | 2.04 B$ |

**Analysis:**  Earnings per share (EPS) and revenue have generally been trending upwards, with a notable jump in the most recent quarter (2025-10-22). This indicates strong financial performance and growth.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $2.51B  | 66.36%        |
| 2025-06-30 | $2.44B  | 66.31%        |
| 2025-03-31 | $2.25B  | 64.69%        |
| 2024-12-31 | $2.41B  | 68.04%        |
| 2024-09-30 | $2.04B  | 67.41%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-09-30 | $16.93B | 4.16%   |
| 2025-06-30 | $17.85B | 3.69%   |
| 2025-03-31 | $17.11B | 4.08%   |
| 2024-12-31 | $16.43B | 4.17%   |
| 2024-09-30 | $15.58B | 3.63%   |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing, demonstrating strong sales performance.
*   **Profit Margin:** Profit margins are exceptionally high and relatively stable, showcasing strong operational efficiency.
*   **Equity:** Equity has generally increased, indicating the company's growing net worth.
*   **ROE (Return on Equity):** ROE is relatively stable, reflecting consistent profitability relative to equity.

**7. Overall Summary**

Intuitive Surgical (ISRG) presents a compelling investment case.

*   **Strengths:** The company has strong historical outperformance compared to the S&P 500, recent positive price momentum, positive media coverage, a "Buy" analyst consensus, strong revenue and profit margins, and a high expected return for long-term investors.
*   **Weaknesses:** The stock is more volatile (Beta > 1).

**Overall Recommendation:** Based on the analysis, ISRG appears to be a promising investment, particularly for long-term investors who can tolerate market volatility. The positive analyst sentiment, strong financial performance, and potential for future growth make it an attractive option.
